CBS 101
Alternative Names: CBS-101Latest Information Update: 06 May 2024
At a glance
- Originator CiRC Biosciences
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinitis pigmentosa
Most Recent Events
- 25 Apr 2024 Preclinical trials in Retinitis pigmentosa in USA (Subretinal) before April 2024 (CiRC Biosciences pipeline, April 2024)